Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bajaj, M.
Right arrow Articles by DeFronzo, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bajaj, M.
Right arrow Articles by DeFronzo, R. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 52:1364-1370, 2003
© 2003 by the American Diabetes Association, Inc.

Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes

Mandeep Bajaj, Swangjit Suraamornkul, Thongchai Pratipanawatr, Lou J. Hardies, Wilailak Pratipanawatr, Leonard Glass, Eugenio Cersosimo, Yoshinori Miyazaki, and Ralph A. DeFronzo

From the Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas

The effect of pioglitazone on splanchnic glucose uptake (SGU), endogenous glucose production (EGP), and hepatic fat content was studied in 14 type 2 diabetic patients (age 50 ± 2 years, BMI 29.4 ± 1.1 kg/m2, HbA1c 7.8 ± 0.4%). Hepatic fat content (magnetic resonance spectroscopy) and SGU (oral glucose load- insulin clamp technique) were quantitated before and after pioglitazone (45 mg/day) therapy for 16 weeks. Subjects received a 7-h euglycemic insulin (100 mU · m-2 · min-1) clamp, and a 75-g oral glucose load was ingested 3 h after starting the insulin clamp. Following glucose ingestion, the steady-state glucose infusion rate during the insulin clamp was decreased appropriately to maintain euglycemia. SGU was calculated by subtracting the integrated decrease in glucose infusion rate during the 4 h after glucose ingestion from the ingested glucose load. 3-[3H]glucose was infused during the initial 3 h of the insulin clamp to determine rates of EGP and glucose disappearance (Rd). Pioglitazone reduced fasting plasma glucose (10.0 ± 0.7 to 7.5 ± 0.6 mmol/l, P < 0.001) and HbA1c (7.8 ± 0.4 to 6.7 ± 0.3%, P < 0.001) despite increased body weight (83 ± 3 to 86 ± 3 kg, P < 0.001). During the 3-h insulin clamp period before glucose ingestion, pioglitazone improved Rd (6.9 ± 0.5 vs. 5.2 ± 0.5 mg · kg-1 · min- 1, P < 0.001) and insulin-mediated suppression of EGP (0.21 ± 0.04 to 0.06 ± 0.02 mg · kg-1 · min-1, P < 0.01). Following pioglitazone treatment, hepatic fat content decreased from 19.6 ± 3.6 to 10.4 ± 2.1%, (P < 0.005), and SGU increased from 33.0 ± 2.8 to 46.2 ± 5.1% (P < 0.005). Pioglitazone treatment in type 2 diabetes 1) decreases hepatic fat content and improves insulin-mediated suppression of EGP and 2) augments splanchnic and peripheral tissue glucose uptake. Improved splanchnic/peripheral glucose uptake and enhanced suppression of EGP contribute to the improvement in glycemic control in patients with type 2 diabetes.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
U. Riserus, D. Sprecher, T. Johnson, E. Olson, S. Hirschberg, A. Liu, Z. Fang, P. Hegde, D. Richards, L. Sarov-Blat, et al.
Activation of Peroxisome Proliferator-Activated Receptor (PPAR){delta} Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men
Diabetes, February 1, 2008; 57(2): 332 - 339.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Sato, Y. Tamura, H. Watada, N. Kumashiro, Y. Igarashi, H. Uchino, T. Maehara, S. Kyogoku, S. Sunayama, H. Sato, et al.
Effects of Diet-Induced Moderate Weight Reduction on Intrahepatic and Intramyocellular Triglycerides and Glucose Metabolism in Obese Subjects
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3326 - 3329.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. G. Tolman, V. Fonseca, A. Dalpiaz, and M. H. Tan
Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease
Diabetes Care, March 1, 2007; 30(3): 734 - 743.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
L. Juurinen, M. Tiikkainen, A.-M. Hakkinen, A. Hakkarainen, and H. Yki-Jarvinen
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E829 - E835.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al.
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 726 - 741.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Ha, M.-J. Kim, B.-K. Choi, J.-J. Rho, D.-J. Oh, T.-H. Rho, K.-H. Kim, H. J. Lee, D.-H. Shin, S. V. Yim, et al.
Positive Association of Obesity with Single Nucleotide Polymorphisms of Syndecan 3 in the Korean Population
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5095 - 5099.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. F. Petersen, S. Dufour, J. Feng, D. Befroy, J. Dziura, C. D. Man, C. Cobelli, and G. I. Shulman
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men
PNAS, November 28, 2006; 103(48): 18273 - 18277.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
G. Ranganathan, R. Unal, I. Pokrovskaya, A. Yao-Borengasser, B. Phanavanh, B. Lecka-Czernik, N. Rasouli, and P. A. Kern
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment
J. Lipid Res., November 1, 2006; 47(11): 2444 - 2450.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
B. Viollet, M. Foretz, B. Guigas, S. Horman, R. Dentin, L. Bertrand, L. Hue, and F. Andreelli
Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders
J. Physiol., July 1, 2006; 574(1): 41 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
L A Adams and P Angulo
Treatment of non-alcoholic fatty liver disease.
Postgrad. Med. J., May 1, 2006; 82(967): 315 - 322.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Gastaldelli, Y. Miyazaki, M. Pettiti, E. Santini, D. Ciociaro, R. A. DeFronzo, and E. Ferrannini
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 806 - 812.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Deng, S. Shan, P.-P. Li, Z.-F. Shen, X.-P. Lu, J. Cheng, and Z.-Q. Ning
Peroxisome Proliferator-Activated Receptor-{gamma} Transcriptionally Up-Regulates Hormone-Sensitive Lipase via the Involvement of Specificity Protein-1
Endocrinology, February 1, 2006; 147(2): 875 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
P. E. Carey, J. Gerrard, G. W. Cline, C. Dalla Man, P. T. English, M. J. Firbank, C. Cobelli, and R. Taylor
Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production
Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E941 - E947.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Malone
Medications Associated with Weight Gain
Ann. Pharmacother., December 1, 2005; 39(12): 2046 - 2054.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. J.G. Hanley, K. Williams, A. Festa, L. E. Wagenknecht, R. B. D'Agostino Jr, and S. M. Haffner
Liver Markers and Development of the Metabolic Syndrome: The Insulin Resistance Atherosclerosis Study
Diabetes, November 1, 2005; 54(11): 3140 - 3147.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Bajaj, S. Suraamornkul, A. Romanelli, G. W. Cline, L. J. Mandarino, G. I. Shulman, and R. A. DeFronzo
Effect of a Sustained Reduction in Plasma Free Fatty Acid Concentration on Intramuscular Long-Chain Fatty Acyl-CoAs and Insulin Action in Type 2 Diabetic Patients
Diabetes, November 1, 2005; 54(11): 3148 - 3153.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Dhindsa, D. Tripathy, N. Sanalkumar, S. Ravishankar, H. Ghanim, A. Aljada, and P. Dandona
Free Fatty Acid-Induced Insulin Resistance in the Obese Is Not Prevented by Rosiglitazone Treatment
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5058 - 5063.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. Staels and J.-C. Fruchart
Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists
Diabetes, August 1, 2005; 54(8): 2460 - 2470.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Tamura, Y. Tanaka, F. Sato, J. B. Choi, H. Watada, M. Niwa, J. Kinoshita, A. Ooka, N. Kumashiro, Y. Igarashi, et al.
Effects of Diet and Exercise on Muscle and Liver Intracellular Lipid Contents and Insulin Sensitivity in Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3191 - 3196.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
K. G. Tolman, V. Fonseca, M. H. Tan, and A. Dalpiaz
Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus
Ann Intern Med, December 21, 2004; 141(12): 946 - 956.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. J.G. Hanley, K. Williams, A. Festa, L. E. Wagenknecht, R. B. D'Agostino Jr., J. Kempf, B. Zinman, and S. M. Haffner
Elevations in Markers of Liver Injury and Risk of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study
Diabetes, October 1, 2004; 53(10): 2623 - 2632.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Yki-Jarvinen
Thiazolidinediones
N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
P. Iozzo, T. Takala, V. Oikonen, J. Bergman, T. Gronroos, E. Ferrannini, P. Nuutila, and J. Knuuti
Effect of Training Status on Regional Disposal of Circulating Free Fatty Acids in the Liver and Skeletal Muscle During Physiological Hyperinsulinemia
Diabetes Care, September 1, 2004; 27(9): 2172 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. J. Nadeau, J. W. Leitner, I. Gurerich, and B. Draznin
Insulin Regulation of Sterol Regulatory Element-binding Protein-1 Expression in L-6 Muscle Cells and 3T3 L1 Adipocytes
J. Biol. Chem., August 13, 2004; 279(33): 34380 - 34387.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Tiikkainen, A.-M. Hakkinen, E. Korsheninnikova, T. Nyman, S. Makimattila, and H. Yki-Jarvinen
Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes
Diabetes, August 1, 2004; 53(8): 2169 - 2176.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith
The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor-{gamma} Target Genes Related to Lipid Storage In Vivo
Diabetes Care, July 1, 2004; 27(7): 1660 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Tonelli, W. Li, P. Kishore, U. B. Pajvani, E. Kwon, C. Weaver, P. E. Scherer, and M. Hawkins
Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes
Diabetes, June 1, 2004; 53(6): 1621 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Bays, L. Mandarino, and R. A. DeFronzo
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Bajaj, S. Suraamornkul, P. Piper, L. J. Hardies, L. Glass, E. Cersosimo, T. Pratipanawatr, Y. Miyazaki, and R. A. DeFronzo
Decreased Plasma Adiponectin Concentrations Are Closely Related to Hepatic Fat Content and Hepatic Insulin Resistance in Pioglitazone-Treated Type 2 Diabetic Patients
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 200 - 206.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. R. Diani, G. Sawada, B. Wyse, F. T. Murray, and M. Khan
Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes
Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E116 - E122.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2003 by the American Diabetes Association.